Tags

Type your tag names separated by a space and hit enter

Therapeutic potential of cannabinoid receptor ligands: current status.
Methods Find Exp Clin Pharmacol 2006; 28(3):177-83MF

Abstract

There are at least two types of cannabinoid receptors, CB1 also named CNR1 and CB2 also named CNR2, both coupled to G proteins. CB1 receptors exist primarily on central and peripheral neurons. CB2 receptors are present mainly on immune cells. Endogenous agonists for cannabinoid receptors (endocannabinoids) have also been discovered, the most important being arachidonoyl ethanolamide (anandamide), 2-arachidonoyl glycerol (2-AG), and 2-archidonyl glyceryl ether. Following their release, endocannabinoids are removed from the extracellular space and then degraded by intracellular enzymic hydrolysis. CB1/CB2 agonists are already used clinically as antiemetic or to stimulate appetite. Potential therapeutic uses of cannabinoid receptor agonists include the management of multiple sclerosis, spinal cord injury, pain, inflammatory disorders, glaucoma, bronchial asthma, vasodilatation that accompanies advanced cirrhosis, and cancer.

Authors+Show Affiliations

Department of Pharmacology, Pt. B.D. Sharma PGIMS, Rohtak, Haryana, India.No affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

16810344

Citation

Singh, J, and S Budhiraja. "Therapeutic Potential of Cannabinoid Receptor Ligands: Current Status." Methods and Findings in Experimental and Clinical Pharmacology, vol. 28, no. 3, 2006, pp. 177-83.
Singh J, Budhiraja S. Therapeutic potential of cannabinoid receptor ligands: current status. Methods Find Exp Clin Pharmacol. 2006;28(3):177-83.
Singh, J., & Budhiraja, S. (2006). Therapeutic potential of cannabinoid receptor ligands: current status. Methods and Findings in Experimental and Clinical Pharmacology, 28(3), pp. 177-83.
Singh J, Budhiraja S. Therapeutic Potential of Cannabinoid Receptor Ligands: Current Status. Methods Find Exp Clin Pharmacol. 2006;28(3):177-83. PubMed PMID: 16810344.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Therapeutic potential of cannabinoid receptor ligands: current status. AU - Singh,J, AU - Budhiraja,S, PY - 2006/7/1/pubmed PY - 2006/9/12/medline PY - 2006/7/1/entrez SP - 177 EP - 83 JF - Methods and findings in experimental and clinical pharmacology JO - Methods Find Exp Clin Pharmacol VL - 28 IS - 3 N2 - There are at least two types of cannabinoid receptors, CB1 also named CNR1 and CB2 also named CNR2, both coupled to G proteins. CB1 receptors exist primarily on central and peripheral neurons. CB2 receptors are present mainly on immune cells. Endogenous agonists for cannabinoid receptors (endocannabinoids) have also been discovered, the most important being arachidonoyl ethanolamide (anandamide), 2-arachidonoyl glycerol (2-AG), and 2-archidonyl glyceryl ether. Following their release, endocannabinoids are removed from the extracellular space and then degraded by intracellular enzymic hydrolysis. CB1/CB2 agonists are already used clinically as antiemetic or to stimulate appetite. Potential therapeutic uses of cannabinoid receptor agonists include the management of multiple sclerosis, spinal cord injury, pain, inflammatory disorders, glaucoma, bronchial asthma, vasodilatation that accompanies advanced cirrhosis, and cancer. SN - 0379-0355 UR - https://www.unboundmedicine.com/medline/citation/16810344/Therapeutic_potential_of_cannabinoid_receptor_ligands:_current_status_ L2 - http://journals.prous.com/journals/servlet/xmlxsl/pk_journals.xml_summaryn_pr?p_JournalId=6&p_RefId=985231 DB - PRIME DP - Unbound Medicine ER -